| 恩度联合XELOX方案一线治疗老年晚期结直肠癌的临床观察 |
| |
| 引用本文： | 严冬,戴红. 恩度联合XELOX方案一线治疗老年晚期结直肠癌的临床观察[J]. 中华肿瘤防治杂志, 2011, 18(12): 961-964 |
| |
| 作者姓名： | 严冬 戴红 |
| |
| 作者单位： | 首都医科大学附属北京朝阳医院肿瘤科,北京,100020 |
| |
| 摘 要： | 目的:观察恩度联合卡培他滨和奥沙利铂(XELOX)一线治疗老年晚期结直肠癌的疗效、疾病进展时间(TTP)、总生存期(OS)及不良反应。方法:回顾性分析了66例经组织病理学确诊的转移性结直肠癌患者的临床资料。XELOX方案化疗(XELOX)30例,恩度联合XELOX方案化疗(XELOXE)36例。2个周期后进行疗效评价。结果:XELOXE组总有效率(RR)44.4%,XELOX组RR30.0%,差异有统计学意义,P=0.04;两组的mT-TP(7个月vs6个月,P=0.014)和mOS(18个月vs16个月,P=0.041)比较,差异均有统计学意义。Ⅲ度以上不良反应主要有末梢神经感觉异常(6.1%)、手足综合征(7.6%)及血小板减少(7.6%)。高血压(8.3%)与心律失常(5.6%)主要为Ⅰ~Ⅱ度。结论:恩度联合XELOX一线治疗老年转移性结直肠癌有较好疗效,且毒性反应轻,耐受性好。
|
| 关 键 词： | 重组人血管内皮抑制素 结直肠肿瘤/药物疗法 |
Endostar combined with the first-line chemotherapy regimen of XELOX in treatment of advanced colorectal cancer in the elderly |
| |
| YAN Dong,DAI Hong. Endostar combined with the first-line chemotherapy regimen of XELOX in treatment of advanced colorectal cancer in the elderly[J]. Chinese Journal of Cancer Prevention and Treatment, 2011, 18(12): 961-964 |
| |
| Authors: | YAN Dong DAI Hong |
| |
| Affiliation: | YAN Dong,DAI HongDepartment of Oncology,Capital Medical University,Beijing Chaoyang Hospital,Beijing 100020,P.R.China |
| |
| Abstract: | OBJECTIVE: To investigate the combination of oxaliplatin(L-OHP),capecitabine and endostar,in the treatment of advanced colorectal cancer in elderly,and explore its efficiency,time to progression(TTP),overall survival(OS) and toxicity.METHODS: The clinical datum of sixty-six patients confirmed by pathology with advanced colorectal cancer,were analyzed retrospectively.Thirty cases of them were treated by L-OHP and capecitabine(XELOX) regimen,36 cases of them were treated by endostar plus chemotherapy(L-OHP an... |
| |
| Keywords: | endostar colorectal neoplasms/drug therapy |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
